Zobrazeno 1 - 10
of 107
pro vyhledávání: '"Analyn, Lizaso"'
Autor:
Kezhong Chen, Guannan Kang, Zhihong Zhang, Analyn Lizaso, Stephan Beck, Iben Lyskjær, Olga Chervova, Bingsi Li, Haifeng Shen, Chenyang Wang, Bing Li, Heng Zhao, Xi Li, Fan Yang, Nnennaya Kanu, Jun Wang
Publikováno v:
BMC Medicine, Vol 21, Iss 1, Pp 1-16 (2023)
Abstract Background The feasibility of DNA methylation-based assays in detecting minimal residual disease (MRD) and postoperative monitoring remains unestablished. We aim to investigate the dynamic characteristics of cancer-related methylation signal
Externí odkaz:
https://doaj.org/article/390a6d2806f24e429166fea95f55be3c
Autor:
Yongchang Zhang, Zhe Huang, Liang Zeng, Xiangyu Zhang, Yizhi Li, Qinqin Xu, Haiyan Yang, Analyn Lizaso, Chunwei Xu, Jun Liu, Wenxian Wang, Zhengbo Song, Sai-Hong Ignatius Ou, Nong Yang
Publikováno v:
npj Precision Oncology, Vol 6, Iss 1, Pp 1-4 (2022)
Abstract This retrospective study investigated the association between the pattern of disease progression and molecular mechanism of acquired resistance in a large cohort of 49 patients with ROS1-rearranged advanced non-small-cell lung cancer treated
Externí odkaz:
https://doaj.org/article/dd3cf035cf4240f082cb514c531b74d9
Autor:
Hang Li, Ze‐Lin Ma, Bin Li, Yun‐jian Pan, Jia‐Qing Xiang, Ya‐Wei Zhang, Yi‐Hua Sun, Ting Hou, Analyn Lizaso, Yan Chen, Xi Li, Hong Hu
Publikováno v:
Cancer Medicine, Vol 10, Iss 23, Pp 8377-8386 (2021)
Abstract Growing efforts are being invested in investigating various molecular approaches to detect minimal residual disease (MRD) and predict disease recurrence. In our study, we investigated the utility of parallel longitudinal analysis of mutation
Externí odkaz:
https://doaj.org/article/f9cf44dbf7b144dd826ad9e7c78bdd6b
Autor:
Yongchang Zhang, Liang Zeng, Xiangyu Zhang, Yizhi Li, Lingli Liu, Qinqin Xu, Haiyan Yang, Wenjuan Jiang, Analyn Lizaso, Luting Qiu, Ting Hou, Jun Liu, Ling Peng, Nong Yang
Publikováno v:
BMC Medicine, Vol 19, Iss 1, Pp 1-11 (2021)
Abstract Background The combination of bevacizumab and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) could prolong progression-free survival (PFS) in patients with EGFR-mutant advanced non-small-cell lung cancer (NSCLC). Our
Externí odkaz:
https://doaj.org/article/91ea5f3f48054fc69935c7709ed104d7
Autor:
Yongchang Zhang, Xiangyu Zhang, Ruiguang Zhang, Qinqin Xu, Haiyan Yang, Analyn Lizaso, Chunwei Xu, Jun Liu, Wenxian Wang, Sai-Hong Ignatius Ou, Jiexia Zhang, Zhengbo Song, Nong Yang
Publikováno v:
BMC Medicine, Vol 19, Iss 1, Pp 1-13 (2021)
Abstract Background ROS1-rearranged lung cancers benefit from first-line crizotinib therapy; however, clinical and molecular factors that could affect crizotinib efficacy in ROS1-rearranged lung cancers are not yet well-elucidated. Our retrospective
Externí odkaz:
https://doaj.org/article/8d3d55c715a84c45ade8c62b76e84bcc
Autor:
Tong Xie, Qin Feng, Zhongwu Li, Ming Lu, Jian Li, Analyn Lizaso, Jianxing Xiang, Lu Zhang, Lin Shen, Zhi Peng
Publikováno v:
Hereditary Cancer in Clinical Practice, Vol 19, Iss 1, Pp 1-6 (2021)
Abstract Background Germline DNA mismatch repair (MMR) gene aberrations are associated with colorectal cancer (CRC) predisposition and high tumor mutation burden (TMB-H), with increased likelihood of favorable response to immune checkpoint inhibitors
Externí odkaz:
https://doaj.org/article/49bea3f12e344df180333d7201a33afd
Autor:
Zhaona Li, Pupu Li, Bing Yan, Qiongqiong Gao, Xiangli Jiang, Zhongli Zhan, Qingna Yan, Analyn Lizaso, Chun Huang
Publikováno v:
Thoracic Cancer, Vol 11, Iss 1, Pp 176-180 (2020)
A 47‐year‐old female with ALK‐rearranged lung adenocarcinoma developed leptomeningeal metastasis (LM) after progression on first‐line crizotinib. Alectinib 300 mg was commenced and the patient achieved clinical and radiographic improvements.
Externí odkaz:
https://doaj.org/article/c89c1918fe3a4b49b061c10f5a8ebb9a
Autor:
Ying Ding, Lihua Zhang, Lingchuan Guo, Chunyan Wu, Jianhua Zhou, Yongchun Zhou, Jie Ma, Xiao Li, Pan Ji, Ming Wang, Weidong Zhu, Chenxi Shi, Sanen Li, Wei Wu, Wei Zhu, Desheng Xiao, Chunyan Fu, Qiuyan He, Rui Sun, Xinru Mao, Analyn Lizaso, Bing Li, Han Han‐Zhang, Zhihong Zhang
Publikováno v:
Thoracic Cancer, Vol 11, Iss 1, Pp 103-112 (2020)
Abstract Background Distinction in the mutational profile between the common histological types, lung adenocarcinoma (LUAD) and squamous cell lung carcinoma (LUSC) has been well‐established. However, comprehensive mutation profiles of the predomina
Externí odkaz:
https://doaj.org/article/40ea46d4d892485e93f3c23ed4963a30
Publikováno v:
Diagnostic Pathology, Vol 14, Iss 1, Pp 1-7 (2019)
Abstract Background The accurate identification of the tissue of origin is critical for optimal management of cancer patients particularly those who develop multiple malignancies; however, conventional diagnostic methods at times may fail to provide
Externí odkaz:
https://doaj.org/article/d61e007ce56841e3b7fb8e787d4908b9
Autor:
Xingsheng Hu, Dongyong Yang, Yalun Li, Li Li, Yan Wang, Peng Chen, Song Xu, Xingxiang Pu, Wei Zhu, Pengbo Deng, Junyi Ye, Hanhan Zhang, Analyn Lizaso, Hao Liu, Xinru Mao, Hai Huang, Qian Chu, Chengping Hu
Publikováno v:
Cancer Biology & Medicine, Vol 16, Iss 3, Pp 556-564 (2019)
Objective Germline alterations in the breast cancer susceptibility genes type 1 and 2, BRCA1 and BRCA2, predispose individuals to hereditary cancers, including breast, ovarian, prostate, pancreatic, and stomach cancers. Accumulating evidence suggests
Externí odkaz:
https://doaj.org/article/4a8ac45845d54b70a92032f071c1c5c8